American journal of clinical pathology最新文献_第6页

Reply to "Performance of GPT-4 Vision on kidney pathology exam questions". 答复 "GPT-4 Vision 在肾脏病理学试题中的表现"。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae059

Jing Miao, Charat Thongprayoon, Wisit Cheungpasitporn, Lynn D Cornell

引用次数: 0

Mobile calculator application for estimating human erythrocyte antigen frequency in Korea. 用于估算韩国人类红细胞抗原频率的移动计算器应用程序。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae070

Dong Woo Shin, Yun Ji Hong, Kyoung Un Park

{"title":"Mobile calculator application for estimating human erythrocyte antigen frequency in Korea.","authors":"Dong Woo Shin, Yun Ji Hong, Kyoung Un Park","doi":"10.1093/ajcp/aqae070","DOIUrl":"10.1093/ajcp/aqae070","url":null,"abstract":"Objectives: This study aimed to establish a comprehensive human erythrocyte antigen (HEA) frequency data set for Koreans. It also sought to develop a mobile app that facilitates the calculation of the frequencies of specific antigen-negative red blood cell units and the average number of units required for antigen typing.Methods: Human erythrocyte antigen frequencies were compiled from large-scale blood donor data and 5 previous papers. Based on the collected data, we developed a mobile calculator app for HEA frequency and evaluated its usability.Results: Human erythrocyte antigen frequency data for 20 blood group systems, including the ABO, Rh, MNS, Duffy, Kidd, and Diego systems, were established. The app was designed to enable users to select the desired phenotype from a drop-down menu and display the calculated frequency at the bottom. The number of units required for antigen typing to find 1 compatible red blood cell unit was also displayed. Five users participated in app evaluation and rated the functionality and information categories highly. In quizzes prompting users to calculate frequencies using the app, all participants provided correct answers, confirming the app's user-friendly functionality.Conclusions: This app, which encompasses comprehensive HEA frequency data, is expected to find multiple uses in transfusion medicine, including optimizing blood bank workflow and defining rare blood groups in Korea.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"521-528"},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141309421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Variations in emergency hemorrhage panel turnaround times in 2 major medical centers using the same laboratory methods. 两家大型医疗中心使用相同实验室方法进行急诊出血检查的周转时间差异。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae071

Matthew E Hogan, Zhinan Liu, Lynn G Stansbury, Monica S Vavilala, John R Hess, Hamilton C Tsang

{"title":"Variations in emergency hemorrhage panel turnaround times in 2 major medical centers using the same laboratory methods.","authors":"Matthew E Hogan, Zhinan Liu, Lynn G Stansbury, Monica S Vavilala, John R Hess, Hamilton C Tsang","doi":"10.1093/ajcp/aqae071","DOIUrl":"10.1093/ajcp/aqae071","url":null,"abstract":"Objectives: Demand for rapid coagulation testing for massive transfusion events led to development of an emergency hemorrhage panel (EHP; hemoglobin, platelet count, prothrombin time/international normalized ratio, and fibrinogen), with laboratory turnaround time (TAT) of less than 20 minutes. Ten years on, we asked if current laboratory practices were meeting that TAT goal and differences were evident in TAT between the 2 major institutions in our system.Methods: We identified EHPs ordered at our 2 largest hospitals, February 2, 2021, to July 17, 2022, comparing order to specimen draw time, specimen draw to specimen received time, laboratory analytic time, and total TAT results from emergency department and operating room. Site 1 houses a level I trauma center; site 2 includes tertiary care, transplant, and obstetrics services.Results: In total, 1137 EHPs were recorded in our study period. Laboratory TAT was significantly faster at site 1 (~14 vs ~27 minutes, P < .01). Average laboratory TAT was under 20 minutes at site 1 but only for 50% of specimens at site 2. Outlier specimens were collection delays at site 1 and specimen processing delays at site 2.Conclusions: The EHP can be performed as rapidly as described. However, compromises in laboratory location, available personnel, and processing differences can degrade performance.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"529-534"},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reply to "Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: a Bone Marrow Pathology Group study". 对 "骨髓增生性肿瘤（不可分类）临床预后的预测因素：骨髓病理学小组的一项研究 "的答复

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae142

Genevieve M Crane, Yan Xie, Heesun J Rogers

引用次数: 0

High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair-proficient colorectal cancers only. 肿瘤基质中的α-SMA高表达仅与错配修复功能良好的结直肠癌的不良临床指标有关。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae145

Declan J Sculthorpe, Amy Denton, Wakkas Fadhil, Dewi Rusnita, Mohammad Ilyas, Abhik Mukherjee

{"title":"High α-SMA expression in the tumor stroma is associated with adverse clinical parameters in mismatch repair-proficient colorectal cancers only.","authors":"Declan J Sculthorpe, Amy Denton, Wakkas Fadhil, Dewi Rusnita, Mohammad Ilyas, Abhik Mukherjee","doi":"10.1093/ajcp/aqae145","DOIUrl":"https://doi.org/10.1093/ajcp/aqae145","url":null,"abstract":"Objectives: As mismatch repair status confers differential prognosis in colorectal cancers, this study aimed to determine associations of α-smooth muscle actin (α-SMA) protein expression in mismatch repair-proficient (pMMR) and mismatch repair-deficient (dMMR) colorectal tumors with clinicopathologic and prognostic features.Methods: Tissue microarrays from patients with colorectal cancer, immunostained with α-SMA, were assessed through digital image analysis. Total (n = 962), pMMR (n = 782), and dMMR (n = 156) stromal H-scores were assessed for associations with clinicopathologic and survival data.Results: Higher α-SMA expression was correlated with pMMR status (P = 5.2223 × 10-8). In the pMMR subgroup, higher α-SMA stromal expression at the tumor periphery was correlated with higher T stage (P = .002), perineural invasion (P = .038), infiltrative tumor edge (P = .01), involved nodal status (P = .036), metastases (P = .013), synchronous metastases (P = .007), recurrence (P = .004), and both 3-year and 5-year survival (P = .018). dMMR tumors showed no significant correlations with α-SMA staining.Conclusions: The findings highlight that immunostaining with α-SMA in pMMR colorectal tumors, especially at the tumor periphery, has the potential to identify patients with adverse prognostic features. Digital assessment of α-SMA may offer improved objectivity, accuracy, economy of time, and risk stratification for management.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical validation of the Ion Torrent Oncomine Myeloid Assay GX v2 on the Genexus Integrated Sequencer as a stand-alone assay for single-nucleotide variants, insertions/deletions, and fusion genes: Challenges, performance, and perspectives. Ion Torrent Oncomine骨髓测定GX v2在Genexus集成测序仪上作为单核苷酸变异、插入/缺失和融合基因的独立测定的临床验证：挑战、性能和前景。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae063

Kritika Krishnamurthy, Jiani Chai, Xiaowei Liu, Yanhua Wang, Rizwan Naeem, D Yitzchak Goldstein

{"title":"Clinical validation of the Ion Torrent Oncomine Myeloid Assay GX v2 on the Genexus Integrated Sequencer as a stand-alone assay for single-nucleotide variants, insertions/deletions, and fusion genes: Challenges, performance, and perspectives.","authors":"Kritika Krishnamurthy, Jiani Chai, Xiaowei Liu, Yanhua Wang, Rizwan Naeem, D Yitzchak Goldstein","doi":"10.1093/ajcp/aqae063","DOIUrl":"10.1093/ajcp/aqae063","url":null,"abstract":"Objectives: Myeloid neoplasms require comprehensive characterization of genetic abnormalities, including single-nucleotide variants, small insertions and deletions, and fusions and translocations for management. The Oncomine Myeloid Assay GX v2 (Thermo Fisher Scientific) analyzes 17 full genes, 28 hotspot genes, 30 fusion driver genes, and 5 expression genes.Methods: The validation set included 192 DNA samples, 28 RNA samples, and 9 cell lines and contrived controls. The DNA and RNA were extracted from both peripheral blood and bone marrow. Library preparation, templating, and sequencing was performed on the fully automated Genexus Integrated Sequencer (Thermo Fisher Scientific). The sequencing data were analyzed by manual curation, default Oncomine filters and the Oncomine Reporter (Thermo Fisher Scientific).Results: Of the 600 reference pathogenic DNA variants targeted by the assay, concordance was seen in 98.3% of unfiltered variant call format files. Precision and reproducibility were 100%, and the lower limit of detection was 2% variant allele frequency for DNA. Inability to detect variants in long homopolymer regions intrinsic to the Ion Torrent chemistry led to 7 missed variants; 100% concordance was seen with reference RNA samples.Conclusions: This extensive clinical validation of the Oncomine Myeloid Assay GX v2 on the Genexus Integrated Sequencer with its built-in bioinformatics pipeline and Ion Torrent Oncomine Reporter shows robust performance in terms of variant calling accuracy, precision, and reproducibility, with the advantage of a rapid turnaround time of 2 days. The greatest limitation is the inability to detect variants in long homopolymer regions.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"480-491"},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tennessee hospital noncompliance with price transparency legislation for 8 common laboratory tests. 田纳西州医院在 8 项常见化验项目上不遵守价格透明法规的情况。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae057

Stephanie A Hart, Ayesha Khan, Garrett S Booth, Joesph R Wiencek

{"title":"Tennessee hospital noncompliance with price transparency legislation for 8 common laboratory tests.","authors":"Stephanie A Hart, Ayesha Khan, Garrett S Booth, Joesph R Wiencek","doi":"10.1093/ajcp/aqae057","DOIUrl":"10.1093/ajcp/aqae057","url":null,"abstract":"Objectives: The goal of this study was to assess hospital compliance with federal price transparency mandates and barriers to pricing information in Tennessee.Methods: All hospitals websites were queried for gross, cash, and BlueCross BlueShield of Tennessee prices for 8 high-frequency laboratory tests in 2 Centers for Medicare & Medicaid Services-mandated pricing sources: (1) a machine-readable file of all available services and (2) a consumer-friendly display of 300 shoppable services. Barriers, including click counts, data availability, and intrahospital price discrepancies, were noted.Results: Of the 145 Tennessee hospitals assessed, 97.2% were noncompliant with the Centers for Medicare & Medicaid Services final rule. Subanalysis of available machine-readable files, price estimators, and shoppable services files demonstrated 49.6%, 95.1%, and 78.6% noncompliance, respectively. Barriers to pricing information included requiring protected health information (55.9%), missing at least 1 pricing source (7.6%), having no pricing sources available (6.2%), and involving more than 3 clicks to access the cash price in machine-readable files (54.1%) and price estimators (68.6%.) Average intrahospital discrepancy for basic metabolic panel cash prices across pricing sources was $101.30 (range, $0-1012.40).Conclusions: Our study showed high levels of noncompliance with price transparency laws, inconsistent and inaccessible pricing, and continued challenges facing patients in Tennessee.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"450-454"},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140908238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

β2-microglobulin expression is associated with aggressive histology, activated tumor immune milieu, and outcome in colon carcinoma. β2-微球蛋白的表达与侵袭性组织学、激活的肿瘤免疫环境和结肠癌的预后有关。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae066

Soo Hyun Lee, Amaya Pankaj, Steffen Rickelt, David Ting, Cristina Ferrone, Deepa T Patil, Omer Yilmaz, David Berger, Vikram Deshpande, Osman Yilmaz

{"title":"β2-microglobulin expression is associated with aggressive histology, activated tumor immune milieu, and outcome in colon carcinoma.","authors":"Soo Hyun Lee, Amaya Pankaj, Steffen Rickelt, David Ting, Cristina Ferrone, Deepa T Patil, Omer Yilmaz, David Berger, Vikram Deshpande, Osman Yilmaz","doi":"10.1093/ajcp/aqae066","DOIUrl":"10.1093/ajcp/aqae066","url":null,"abstract":"Objectives: We sought to assess the expression of human leukocyte antigen (HLA) proteins and β2-microglobulin (B2M) in tumor cells and the relationship with immune microenvironment and outcome in colorectal cancer (CRC).Methods: A total of 953 CRC cases were evaluated by immunohistochemistry for HLA class I, HLA class II, and B2M. The expression level of these biomarkers was correlated with clinicopathologic information, BRAF V600E and mismatch repair (MMR) proteins, and the quantitated expression levels of immune cells (CD8 and CD163) and immune regulatory proteins (FoxP3, programmed cell death 1 ligand 1 [PD-L1], and LAG3).Results: We found that B2M-low tumors were statistically correlated with aggressive histologic features, including higher stage, higher grade, extramural venous invasion, perineural invasion, and distant metastasis. Expression of B2M was positively correlated (R2 = 0.3) and significantly associated with MMR-deficient tumors (P < .001); B2M-low tumors were also associated with an \"immune cold\"' microenvironment, including a reduced number of immune cells (CD8 and CD163), reduced expression of immune regulatory proteins by immune cells (PD-L1, FoxP3, and LAG3), and reduced tumor cell expression of PD-L1. These B2M-low tumors correlated with lower disease-specific survival (P = .018), a finding that maintained significance only for the proficient MMR cohort (P = .037).Conclusions: Our findings suggest that B2M expression may support predictive models for both outcome and checkpoint inhibitor therapy treatment response for colorectal adenocarcinoma.","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"500-508"},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141309422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Performance of GPT-4 Vision on kidney pathology exam questions. GPT-4 Vision 在肾脏病理学试题上的表现。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae058

Hinpetch Daungsupawong, Viroj Wiwanitkit

引用次数: 0

Regarding the predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable. 关于骨髓增生性肿瘤临床结果的预测因素，无法分类。

IF 2.3 4区医学

American journal of clinical pathology Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae141

Shengquan Chen, Chunyang Zhou

引用次数: 0